Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2019

View Archived Issues

lncRNA 00607 as a tumor suppressor in hepatocellular carcinoma

Intrabone gene therapy with autologous HSCs for transfusion-dependent beta-thalassemia: phase I/II

Collateral undamage: novel arterial growth mechanism underlies neonatal heart regeneration

Mannin Research and McMaster University enter glaucoma drug collaboration

NIAID initiates phase I study of the VRC-HIVRGP096-00-VP HIV vaccine

Myelin can regenerate in MS but mostly doesn't

Recombination, mutation probabilities linked

Immunosuppressive peptide R9-SOCS1-KIR prevents ocular damage in models of autoimmune uveitis

VCN-01 shows promising activity in preclinical models and in phase I study of retinoblastoma

Novo Nordisk initiates phase I pharmacokinetic study of NNC0148-0287sema in type 2 diabetes

New phase I trial investigates use of MK-5475 in moderate to severe PAH

SRPK1 found as therapeutic target for treating acute myeloid leukemia

I-Mab Biopharma begins first-in-human study of TJ-003234

Withyou Biotechnology describes new ACE inhibitors

Destiny Pharma reports data from second phase I safety study of XF-73

FDA approves Imbruvica with obinutuzumab for treatment-naive CLL/SLL

Vaccine targeting mucin-1 designed to function in immunotolerant hosts

Phase III study of Ultomiris in aHUS meets primary objective of complete TMA response

FDA lifts partial clinical hold on phase I studies of MGD-009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Rare earth: Biomarin to use global reach post-$4.8B Amicus buy
BioWorld
Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...